These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20392250)

  • 1. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
    Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S
    Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
    Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
    Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
    Wu SF; Liu TM; Lin YC; Sytwu HK; Juan HF; Chen ST; Shen KL; Hsi SC; Hsieh SL
    J Leukoc Biol; 2004 Feb; 75(2):293-306. PubMed ID: 14634066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
    Lin WW; Hsieh SL
    Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
    Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
    Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.
    Han B; Bojalil R; Amezcua-Guerra LM; Springall R; Valderrama-Carvajal H; Wu J; Luo H
    Int Immunol; 2008 Aug; 20(8):1067-75. PubMed ID: 18562337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome.
    Chen CY; Yang KY; Chen MY; Chen HY; Lin MT; Lee YC; Perng RP; Hsieh SL; Yang PC; Chou TY
    Am J Respir Crit Care Med; 2009 Oct; 180(8):751-60. PubMed ID: 19644047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
    Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
    Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.
    Lee CS; Hu CY; Tsai HF; Wu CS; Hsieh SL; Liu LC; Hsu PN
    Clin Exp Immunol; 2008 Mar; 151(3):383-90. PubMed ID: 18190609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.
    Tang CH; Hsu TL; Lin WW; Lai MZ; Yang RS; Hsieh SL; Fu WM
    J Biol Chem; 2007 Jan; 282(4):2346-54. PubMed ID: 17099218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.